Neon Therapeutics closes $70M Series B

January 06, 2017

Share:

Drug Discovery | Cambridge, MA | Series B

Immuno-oncology company Neon Therapeutics develops cancer treatments, with a neoantigen vaccine that’s currently in clinical trials. The biotech raised a $55 million Series A in 2015 at a valuation of $82 million.